Eosinophil and lymphocyte counts predict bevacizumab response and survival in recurrent glioblastoma

BACKGROUND: There is a lack of biomarkers to identify glioblastoma (GBM) patients who may benefit from specific salvage therapies, such as the anti-angiogenic agent bevacizumab. We hypothesized that circulating blood counts may serve as biomarkers for treatment response and clinical outcomes. METHOD...

Descripción completa

Detalles Bibliográficos
Autores principales: Vaios, Eugene J, Winter, Sebastian F, Muzikansky, Alona, Nahed, Brian V, Dietrich, Jorg
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Clinical Investigations
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7212859/
https://www.ncbi.nlm.nih.gov/pubmed/32642690
http://dx.doi.org/10.1093/noajnl/vdaa031

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7212859/
https://www.ncbi.nlm.nih.gov/pubmed/32642690
http://dx.doi.org/10.1093/noajnl/vdaa031

Ejemplares similares